Literature DB >> 19072290

Marrow cell infusion attenuates vascular remodeling in a murine model of monocrotaline-induced pulmonary hypertension.

Jason M Aliotta1, Patrick J Keaney, Rod R Warburton, Michael DelTatto, Mark S Dooner, Michael A Passero, Peter J Quesenberry, James R Klinger.   

Abstract

There have been reports of marrow cells converting into pulmonary epithelial cells after marrow transplantation in irradiated mice. We evaluated the impact of whole bone marrow (WBM) infusion in mice, with or without total body irradiation (TBI), treated with saline or monocrotaline (MCT), which induces pulmonary hypertension (PH). C57BL/6 mice were injected with MCT or saline weekly for 4 weeks. Cohorts were then infused with saline vehicle (vehicle) or WBM from C57BL/-Tg(UBC-GFP)30Scha/J mice, with or without previous TBI (WBM or WBM/TBI). Four weeks later, right ventricular peak pressures (RVPP), right ventricular free wall-to-body weight ratios (RV/BW), and pulmonary vessel wall thickness-to-blood vessel diameter ratios (PVWT/D) were determined. WBM infusion and WBM following TBI induced increases in RVPP and RV/BW in saline-treated mice, while only TBI-exposed mice showed additional increases in PVWT/D. MCT increased RVPP, RV/BW, and PVWT/D in mice given vehicle or WBM alone, but not in mice given WBM/TBI. RVPP and RV/BW were not significantly lower in MCT mice given WBM/TBI than in MCT mice treated with vehicle, but MCT-treated mice given WBM or TBI/WBM had significantly lower PVWT/D compared to MCT-treated mice given saline vehicle. No donor WBM-derived pulmonary vascular cells were detected, suggesting that the observed effects of WBM infusion may be due to paracrine effects separate from cell conversions. The observation of PH after marrow infusion suggests an additional mechanism for lung toxicity seen in marrow transplantation. In conclusion, WBM alone appears to increase RVPP and RV/BW in normal mice but the combination of WBM and TBI attenuates MCT-induced PH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19072290      PMCID: PMC3135187          DOI: 10.1089/scd.2008.0237

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  32 in total

1.  Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell.

Authors:  D S Krause; N D Theise; M I Collector; O Henegariu; S Hwang; R Gardner; S Neutzel; S J Sharkis
Journal:  Cell       Date:  2001-05-04       Impact factor: 41.582

2.  Pluripotency of mesenchymal stem cells derived from adult marrow.

Authors:  Yuehua Jiang; Balkrishna N Jahagirdar; R Lee Reinhardt; Robert E Schwartz; C Dirk Keene; Xilma R Ortiz-Gonzalez; Morayma Reyes; Todd Lenvik; Troy Lund; Mark Blackstad; Jingbo Du; Sara Aldrich; Aaron Lisberg; Walter C Low; David A Largaespada; Catherine M Verfaillie
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

3.  Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation.

Authors:  Jason M Aliotta; Fermin M Sanchez-Guijo; Gerri J Dooner; Kevin W Johnson; Mark S Dooner; Kenneth A Greer; Deborah Greer; Jeffrey Pimentel; Luiz M Kolankiewicz; Napoleon Puente; Sam Faradyan; Paulette Ferland; Elaine L Bearer; Michael A Passero; Mehrdad Adedi; Gerald A Colvin; Peter J Quesenberry
Journal:  Stem Cells       Date:  2007-06-07       Impact factor: 6.277

4.  Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice.

Authors:  Naveen Gupta; Xiao Su; Boris Popov; Jae Woo Lee; Vladimir Serikov; Michael A Matthay
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

5.  Radiation pneumonitis in mice: a severe injury model for pneumocyte engraftment from bone marrow.

Authors:  Neil D Theise; Octavian Henegariu; Joanna Grove; Jayishree Jagirdar; Peter N Kao; James M Crawford; Sunil Badve; Romil Saxena; Diane S Krause
Journal:  Exp Hematol       Date:  2002-11       Impact factor: 3.084

6.  G-CSF in patients suffering from late revascularized ST elevation myocardial infarction: analysis on the timing of G-CSF administration.

Authors:  Markus G Engelmann; Hans D Theiss; Christine Theiss; Armin Huber; Bernd J Wintersperger; Anja E Werle-Ruedinger; Stefan O Schoenberg; Gerhard Steinbeck; Wolfgang-M Franz
Journal:  Exp Hematol       Date:  2008-03-17       Impact factor: 3.084

7.  G-CSF treatment after myocardial infarction: impact on bone marrow-derived vs cardiac progenitor cells.

Authors:  Stefan Brunner; Bruno C Huber; Rebekka Fischer; Michael Groebner; Marcus Hacker; Robert David; Marc-Michael Zaruba; Marcus Vallaster; Christoph Rischpler; Andrea Wilke; Armin Gerbitz; Wolfgang-Michael Franz
Journal:  Exp Hematol       Date:  2008-03-17       Impact factor: 3.084

Review 8.  Role of adult bone marrow stem cells in the repair of ischemic myocardium: current state of the art.

Authors:  Silvia Charwat; Mariann Gyöngyösi; Irene Lang; Senta Graf; Gilbert Beran; Rayyan Hemetsberger; Noemi Nyolczas; Heinz Sochor; Dietmar Glogar
Journal:  Exp Hematol       Date:  2008-03-20       Impact factor: 3.084

Review 9.  G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment?

Authors:  Rasmus Sejersten Ripa; Jens Kastrup
Journal:  Exp Hematol       Date:  2008-03-20       Impact factor: 3.084

10.  Bone marrow-derived cells as progenitors of lung alveolar epithelium.

Authors:  D N Kotton; B Y Ma; W V Cardoso; E A Sanderson; R S Summer; M C Williams; A Fine
Journal:  Development       Date:  2001-12       Impact factor: 6.868

View more
  8 in total

1.  Cellular phenotype and extracellular vesicles: basic and clinical considerations.

Authors:  Peter J Quesenberry; Laura R Goldberg; Jason M Aliotta; Mark S Dooner; Mandy G Pereira; Sicheng Wen; Giovanni Camussi
Journal:  Stem Cells Dev       Date:  2014-04-01       Impact factor: 3.272

2.  The Role of Bone Marrow-derived Cells in Pulmonary Arterial Hypertension. What Lies Beneath?

Authors:  Ivana Nikolic; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

3.  C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade.

Authors:  Brian Casserly; Jeffrey M Mazer; Alexander Vang; Elizabeth O Harrington; James R Klinger; Sharon Rounds; Gaurav Choudhary
Journal:  Life Sci       Date:  2011-07-27       Impact factor: 5.037

4.  Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in Rats.

Authors:  James R Klinger; Mandy Pereira; Michael Del Tatto; Alexander S Brodsky; Keith Q Wu; Mark S Dooner; Theodore Borgovan; Sicheng Wen; Laura R Goldberg; Jason M Aliotta; Corey E Ventetuolo; Peter J Quesenberry; Olin D Liang
Journal:  Am J Respir Cell Mol Biol       Date:  2020-05       Impact factor: 6.914

5.  A novel p38 mitogen-activated protein kinase/Elk-1 transcription factor-dependent molecular mechanism underlying abnormal endothelial cell proliferation in plexogenic pulmonary arterial hypertension.

Authors:  Monal Patel; Dan Predescu; Rajive Tandon; Cristina Bardita; Jennifer Pogoriler; Sangeeta Bhorade; Minhua Wang; Suzy Comhair; Anna Ryan Hemnes; Anna Ryan-Hemnes; Jiwang Chen; Roberto Machado; Aliya Husain; Serpil Erzurum; Sanda Predescu
Journal:  J Biol Chem       Date:  2013-07-26       Impact factor: 5.157

6.  Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline.

Authors:  Francesca Seta; Mahboubeh Rahmani; Patricia V Turner; Colin D Funk
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

7.  Effect of dose, dosing intervals, and hypoxic stress on the reversal of pulmonary hypertension by mesenchymal stem cell extracellular vesicles.

Authors:  James R Klinger; Mandy Pereira; Michael Del Tatto; Mark S Dooner; Sicheng Wen; Peter J Quesenberry; Olin D Liang
Journal:  Pulm Circ       Date:  2021-10-21       Impact factor: 3.017

Review 8.  Myeloid-Derived Suppressor Cells and Pulmonary Hypertension.

Authors:  Andrew J Bryant; Borna Mehrad; Todd M Brusko; James D West; Lyle L Moldawer
Journal:  Int J Mol Sci       Date:  2018-08-03       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.